Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Первичные опухоли центральной нервной системы

Список литературы

  1. Высоцкая И.В. Эндокринно-чувствительные опухоли репродуктивной системы: руководство для врачей. М.: Спец. изд-во мед. кн. (СИМК). 2014. 126 p.
  2. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2018. 250 p.
  3. Agarwal I., Blanco L. WHO classification. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/breastmalignantwhoclassification.html.
  4. Brierley J.D., Gospodarowicz M.K., Wittekind C. TNM Classification of Malignant Tumours, 8th Edition (UIJCC).
  5. Gradishar W.J., Anderson B.O., Blair S.L. et al. Breast cancer version 3.2014. J Natl Compr Canc Netw 2014;12(4):542–590.
  6. Hassan L.M. et al. Evaluation of effect of self-examination and physical examination on breast cancer. Breast Edinb Scotl 2015;24(4):487–490.
  7. Liu X., Meng Q.H., Ye Y. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer.PubMed NCBI 2015;36(2):243– 248.
  8. Elyasinia F., Keramati M.R., Ahmadi F. Neutrophil-Lymphocyte Ratio in Different Stages of Breast Cancer. Acta Med Iran 2017;55(4):228–232.
  9. Vernieri C., Mennitto A.3., Prisciandaro M., Prisciandaro M. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. Sci Rep 2018;8(1):8703.
  10. Lindkær-Jensen S. et al. Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substance. Drug Des Devel Ther 2015;9:1481–1490.
  11. Tas F., Kilic L., Duranyildiz D. Coagulation tests show significant differences in patients with breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med 2014;35(6):5985–5992.
  12. Pedersen L.M., Sørensen P.G. Increased urinary albumin excretion rate in breast cancer patients. Acta Oncol Stockh Swed 2000;39(2):145–149.
  13. Hammond M.E.H. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134(7):e48–72.
  14. Wolff A.C. et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract 2018;14(7):437–441.
  15. Schmid P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018;379(22):2108–2121.
  16. Andre F. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med 2019;380:1929–40. DOI: 10.1056/NEJMoa1813904.
  17. Regan M.M. Predicting Benefit of Endocrine Therapy for Early Breast Cancer. Breast Edinb Scotl 2015;24(0 2):S129–S131.
  18. Tevaarwerk A.J. et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 2014;32(35):3948–3958.
  19. Bernhard J. et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 2014;32:557–557.
  20. Bernhard J. et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 2014;32(15_suppl):557– 557.
  21. Viale G. et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011;22(10):2201–2207.

  1. Zhang X.-H., Xiao C. Diagnostic Value of Nineteen Different Imaging Methods for Patients with Breast Cancer: a Network Meta-Analysis. Cell Physiol Biochem 2018;46(5):2041–2055.
  2. Myers R.E. et al. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ Can Med Assoc J 2001;164(10):1439–1444.
  3. Crump M. et al. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol Off J Am Soc Clin Oncol 1996;14(1):66–69.
  4. Rayter Z. et al. Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 1994;20(2):134–140.
  5. Kosmin M. et al. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur J Cancer Oxf Engl 1990 2017;77:109–116.
  6. Wang M. et al. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta- analysis. Breast Edinb Scotl 2017;31:157–166.
  7. Petrelli F. et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 2015;153(3):477–491.
  8. Wülfing P. et al. Prognostic value of HER2-positive circulating tumor cells in breast cancer patients. Cancer Res 2006;66(8 Supplement):458–459.
  9. Noordhoek I. et al. Higher ER load is not associated with better outcome in stage 1–3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer. Breast Cancer Res Treat 2019;176(1):27–36.
  10. Barco I. et al. Role of axillary ultrasound, magnetic resonance imaging, and ultrasound-guided fine-needle aspiration biopsy in the preoperative triage of breast cancer patients. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 2017;19(6):704–710.
  11. Yu Y.-H. et al. Axillary fine needle aspiration cytology is a sensitive and highly specific technique for the detection of axillary lymph node metastasis: a meta-analysis and systematic review. Cytopathology 2016;27(1):59–69.
  12. Wang X.-W. et al. Diagnostic accuracy of ultrasonograph guided fine-needle aspiration cytologic in staging of axillary lymph node metastasis in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev APJCP 2012;13(11):5517–5523.
  13. Liikanen J. et al. Breast cancer prognosis and isolated tumor cell findings in axillary lymph nodes after core needle biopsy and fine needle aspiration cytology: Biopsy method and breast cancer outcome. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2016;42(1):64–70.
  14. Scully O.J. et al. Breast cancer metastasis. Cancer Genomics Proteomics 2012;9(5):311–320.
  15. Gradishar W.J. et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN 2016;14(3):324–354.
  16. Стенина М.Б., Жукова Л.Г., Королева И.А. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли 2018;8:113–144.
  17. Coates A.S. et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol Off J Eur Soc Med Oncol 2015;26(8):1533–1546.
  18. du Rusquec P. et al. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Therapeutic Advances in Medical Oncology 2020;12:175.
  19. Fares J. et al. Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations. Clin Breast Cancer 2019;19(6):383–391.
  20. Arab C. et al. Cardiac autonomic modulation impairments in advanced breast cancer patients. Clin Res Cardiol Off J Ger Card Soc 2018;107(10):924–936.
  21. García-Manero M. et al. Pregnancy associated breast cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2009;35(2):215–218.
  22. Peccatori F.A. et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2013;24(Suppl 6):vi160–170.
  23. Stensheim H. et al. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer 2011;129(5):1225–1236.
  24. Shachar S.S. et al. Multidisciplinary Management of Breast Cancer During Pregnancy. The Oncologist 2017;22(3):324–334.
  25. Keleher A.J. et al. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 2002;194(1):54–64.

  1. NCCN Clinical Practice Guidelines in Oncology for Older Adult Oncology [Electronic resource]. National Comprehensive Cancer Network. 2019. URL: https://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=1578 (accessed: 18.12.2019).
  2. Ferreira Poloni P. et al. Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study. Climacteric J Int Menopause Soc 2017;20(5):491– 497.
  3. Budach W. et al. DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al 2015;191(8):623–633.
  4. Wang G.-L. et al. Radioactive seed localization and wire guided localization in breast cancer: A systematic review and meta-analysis. J BUON Off J Balk Union Oncol 2019;24(1):48–60.
  5. Serban M. et al. Computed tomography-based virtual simulation versus ultrasound-based clinical setup in electron breast boost radiotherapy: Methodology for CT-based electron virtual simulation. Phys Medica PM Int J Devoted Appl Phys Med Biol Off J Ital Assoc Biomed Phys AIFB 2019;67:100–106.
  6. Marks L.B. Use of normal tissue complication probability models in the clinic. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) /L.B. Marks. Int J Radiat Oncol Biol Phys 2010;76(3):120–145.
  7. ICRU Report 50, Report 62. Journal of the ICRU Issueded:1 November 1999; ICRU Report 83. Journal of the ICRU 2010;10(1).
  8. Gradishar W. J. et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network Journal of the National Comprehensive Cancer Network 2020;18(4),452–478.
  9. Cardoso F., Kyriakides S., Ohno S. ESMO Clinical Practice Guidelines | Early Breast Cancer | ESMO 2019;(1194–1220):30.
  10. Dunne C. et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol Off J Am Soc Clin Oncol 2009;27(10):1615–1620.
  11. Rizki H., Nkonde C., Ching R. C., Kumiponjera D. & Malata C. M. Plastic surgical management of the contralateral breast in post-mastectomy breast reconstruction. International Journal of Surgery 2013:11(9):767–772.
  12. Kirby A.N. et al. Tumour bed delineation for partial breast/breast boost radiotherapy: what is the optimal number of implanted markers? Radiother Oncol J Eur Soc Ther Radiol Oncol 2013;106(2):231–235.
  13. Naoura I. et al. Factors influencing the decision to offer immediate breast reconstruction after mastectomy for ductal carcinoma in situ (DCIS): The Institut Gustave Roussy Breast Cancer Study Group experience. The Breast 2013;22(5):673–675.
  14. Thiessen F. E. F., Tjalma W. A. A., Tondu T. Breast reconstruction after breast conservation therapy for breast cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 2018;230:233–238.
  15. Lyman G.H., Giuliano A.E., Somerfield M.R. et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005 Oct 20;23(30):7703–20. Epub 2005 Sep 12.
  16. Iida S. et al. Evaluation of sentinel lymph node biopsy in clinically node-negative breast cancer. J Nippon Med Sch Nippon Ika Daigaku Zasshi 2011;78(2):96–100.
  17. Huang T. W. et al. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system. International Journal of Surgery 2016; (34):73–80.
  18. Clements K. et al. Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2015;41(10):1406–1410.
  19. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group. Bijker N. et al. Breast- conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group J Clin Oncol 2006 Jul 20;24(21):3381–7. Epub 2006 Jun 26.
  20. Shurell E. et al. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. Cancer 2018;124(1):46–54.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*